New combo aims to keep myeloma in check after CAR-T
Disease control
Recruiting now
This study tests whether a combination of elotuzumab, iberdomide, and dexamethasone can help control multiple myeloma that has returned or not responded to treatment, after patients have already received a CAR-T cell therapy called idecabtagene vicleucel. About 49 adults with rel…
Phase: PHASE1, PHASE2 • Sponsor: Omar Nadeem, MD • Aim: Disease control
Last updated May 17, 2026 00:49 UTC